Cristina Abad Bouzán, Spain
HELL Mental saludAuthor Of 1 Presentation
Uses of clozapine and depot treatment in patients diagnosed with schizophrenia in Calatayud’s region - EPV1322
Abstract
Introduction
Data on the use of clozapine and injectable antipsychotics in patients with schizophrenia has been a study source in several articles in recent years, demonstrating heterogeneity and a big variability in the prescriptions.
Objectives
Our goal is to compare these data with those obtained in Calatayud’s Region, assess whether there are differences to initiate future strategies to be proposed.
Methods
We access and review data on clozapine consumption and use of depot treatment in patients diagnosed with schizophrenia and under follow-up by the Calatayud Mental Health Unit.
Results
Patients diagnosed with schizophrenia in this territory compromise around 0.21% of their total population (64.3% men and 35.7% women). The mean age of the user is 49.85 years, the median and the mode 50 years. Patients diagnosed with schizophrenia on treatment with Clozapine are 13.1% of patients under treatment, 41.7% use Depot injections and 2.38% of patients use both.
Conclusions
Global prescribing data for Clozapine and Depot injections in patients diagnosed with schizophrenia in the area we studied (Calatayud) are similiar to data collected in other national studies.
Presenter of 1 Presentation
Uses of clozapine and depot treatment in patients diagnosed with schizophrenia in Calatayud’s region - EPV1322
Abstract
Introduction
Data on the use of clozapine and injectable antipsychotics in patients with schizophrenia has been a study source in several articles in recent years, demonstrating heterogeneity and a big variability in the prescriptions.
Objectives
Our goal is to compare these data with those obtained in Calatayud’s Region, assess whether there are differences to initiate future strategies to be proposed.
Methods
We access and review data on clozapine consumption and use of depot treatment in patients diagnosed with schizophrenia and under follow-up by the Calatayud Mental Health Unit.
Results
Patients diagnosed with schizophrenia in this territory compromise around 0.21% of their total population (64.3% men and 35.7% women). The mean age of the user is 49.85 years, the median and the mode 50 years. Patients diagnosed with schizophrenia on treatment with Clozapine are 13.1% of patients under treatment, 41.7% use Depot injections and 2.38% of patients use both.
Conclusions
Global prescribing data for Clozapine and Depot injections in patients diagnosed with schizophrenia in the area we studied (Calatayud) are similiar to data collected in other national studies.